Arbutus Biopharma Corp - Asset Resilience Ratio
Arbutus Biopharma Corp (ABUS) has an Asset Resilience Ratio of 77.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Arbutus Biopharma Corp asset portfolio for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2025)
This chart shows how Arbutus Biopharma Corp's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Arbutus Biopharma Corp to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Arbutus Biopharma Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABUS stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $73.46 Million | 77.64% |
| Total Liquid Assets | $73.46 Million | 77.64% |
Asset Resilience Insights
- Very High Liquidity: Arbutus Biopharma Corp maintains exceptional liquid asset reserves at 77.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arbutus Biopharma Corp Industry Peers by Asset Resilience Ratio
Compare Arbutus Biopharma Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual Asset Resilience Ratio data for Arbutus Biopharma Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 77.64% | $73.46 Million | $94.62 Million | +12.12pp |
| 2024-12-31 | 65.52% | $86.29 Million | $131.71 Million | -3.54pp |
| 2023-12-31 | 69.06% | $99.72 Million | $144.40 Million | +9.63pp |
| 2022-12-31 | 59.43% | $116.14 Million | $195.42 Million | +36.92pp |
| 2021-12-31 | 22.51% | $46.03 Million | $204.49 Million | -29.29pp |
| 2020-12-31 | 51.81% | $71.02 Million | $137.08 Million | -4.13pp |
| 2019-12-31 | 55.94% | $59.03 Million | $105.53 Million | +17.47pp |
| 2018-12-31 | 38.47% | $87.67 Million | $227.91 Million | +8.07pp |
| 2017-12-31 | 30.40% | $72.10 Million | $237.20 Million | -8.42pp |
| 2016-12-31 | 38.82% | $107.10 Million | $275.90 Million | +36.78pp |
| 2015-12-31 | 2.04% | $14.53 Million | $712.29 Million | -31.80pp |
| 2014-12-31 | 33.84% | $40.00 Million | $118.20 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $71.72 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $52.60 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $13.70 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $21.02 Million | -- |
| 2009-12-31 | 0.00% | $0.00 | $41.95 Million | -- |
| 2008-12-31 | 11.12% | $4.71 Million | $42.34 Million | -- |
| 2007-12-31 | 0.00% | $0.00 | $24.83 Million | -- |
| 2006-12-31 | 0.00% | $0.00 | $6.03 Million | -- |
| 2005-12-31 | 0.00% | $0.00 | $18.50 Million | -- |
| 2004-12-31 | 0.00% | $0.00 | $41.10 Million | -- |
| 2003-12-31 | 7.19% | $3.65 Million | $50.73 Million | -26.00pp |
| 2002-12-31 | 33.20% | $17.67 Million | $53.22 Million | +0.76pp |
| 2001-12-31 | 32.44% | $21.93 Million | $67.60 Million | -34.98pp |
| 2000-12-31 | 67.41% | $21.93 Million | $32.52 Million | +37.18pp |
| 1999-12-31 | 30.24% | $8.71 Million | $28.80 Million | -5.51pp |
| 1998-12-31 | 35.75% | $5.66 Million | $15.83 Million | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more